173 related articles for article (PubMed ID: 18363211)
21. Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma.
Mego M; Reckova M; Obertova J; Sycova-Mila Z; Brozmanova K; Mardiak J
Ann Oncol; 2007 Nov; 18(11):1906-7. PubMed ID: 17993633
[No Abstract] [Full Text] [Related]
22. [New therapeutic options for advanced thyroid cancer].
Willhauck MJ; Schott M; Kreissl MC; Fassnacht M; Spitzweg C
Dtsch Med Wochenschr; 2011 Jun; 136(22):1165-8. PubMed ID: 21611920
[No Abstract] [Full Text] [Related]
23. Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies.
Strumberg D
J Clin Oncol; 2008 Jul; 26(20):3469-71; author reply 2471. PubMed ID: 18612169
[No Abstract] [Full Text] [Related]
24. [Cutaneous side effects of sorafenib and sunitinib].
Autier J; Mateus C; Wechsler J; Spatz A; Robert C
Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102
[No Abstract] [Full Text] [Related]
25. The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
Desar IM; Mulder SF; Stillebroer AB; van Spronsen DJ; van der Graaf WT; Mulders PF; van Herpen CM
Acta Oncol; 2009; 48(6):927-31. PubMed ID: 19452305
[No Abstract] [Full Text] [Related]
26. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
Patel TV; Morgan JA; Demetri GD; George S; Maki RG; Quigley M; Humphreys BD
J Natl Cancer Inst; 2008 Feb; 100(4):282-4. PubMed ID: 18270341
[No Abstract] [Full Text] [Related]
27. Multitargeted agents for therapeutically challenging tumor: an introduction for oncology nurses.
King CR
ONS News; 2006; 21(8 Suppl):57-8. PubMed ID: 16925154
[No Abstract] [Full Text] [Related]
28. American Society of Clinical Oncology--43rd annual meeting. Translating research into practice.
Kibble A; Shumoogam J
IDrugs; 2007 Aug; 10(8):509-12. PubMed ID: 17665319
[No Abstract] [Full Text] [Related]
29. Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib.
von Bubnoff N; Rummelt C; Menzel H; Sigl M; Peschel C; Duyster J
Leukemia; 2010 Aug; 24(8):1523-5. PubMed ID: 20520641
[No Abstract] [Full Text] [Related]
30. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA
J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201
[No Abstract] [Full Text] [Related]
31. New weapons to snuff out kidney cancer.
Wetherbee SL
Nursing; 2006 Dec; 36(12 Pt.1):58-63; quiz 64. PubMed ID: 17135925
[TBL] [Abstract][Full Text] [Related]
32. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
Lacouture ME; Reilly LM; Gerami P; Guitart J
Ann Oncol; 2008 Nov; 19(11):1955-61. PubMed ID: 18550575
[TBL] [Abstract][Full Text] [Related]
33. About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here?
Aragon-Ching JB; Dahut WL
Ann Oncol; 2010 Jan; 21(1):183-4. PubMed ID: 19903718
[No Abstract] [Full Text] [Related]
34. Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
Shaheen PE; Rini BI; Bukowski RM
Clin Genitourin Cancer; 2006 Jun; 5(1):78-81. PubMed ID: 16859583
[TBL] [Abstract][Full Text] [Related]
35. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
[TBL] [Abstract][Full Text] [Related]
36. Genetic basis of kidney cancer: a model for developing molecular-targeted therapies.
Vira MA; Novakovic KR; Pinto PA; Linehan WM
BJU Int; 2007 May; 99(5 Pt B):1223-9. PubMed ID: 17441915
[No Abstract] [Full Text] [Related]
37. [Renal cell carcinoma].
Obara W; Fujioka T
Gan To Kagaku Ryoho; 2008 Sep; 35(9):1482-7. PubMed ID: 18799901
[TBL] [Abstract][Full Text] [Related]
38. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
[TBL] [Abstract][Full Text] [Related]
39. Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm.
Sulkes A
Isr Med Assoc J; 2010 Oct; 12(10):628-32. PubMed ID: 21090521
[TBL] [Abstract][Full Text] [Related]
40. Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour.
Domont J; Massard C; Lassau N; Armand JP; Le Cesne A; Soria JC
Invest New Drugs; 2010 Apr; 28(2):199-202. PubMed ID: 19352594
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
